{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T21:15:42Z","timestamp":1784754942115,"version":"3.55.0"},"reference-count":38,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2025]]},"DOI":"10.3960\/jslrt.25050","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T22:08:26Z","timestamp":1766527706000},"page":"253-258","source":"Crossref","is-referenced-by-count":1,"title":["Chimeric antigen receptor T-cell and bispecific antibody therapies for follicular lymphoma: Recent advances and future prospects"],"prefix":"10.3960","volume":"65","author":[{"given":"Tsutomu","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Chihara D, Ito H, Matsuda T et al.<\/i> Differences in Incidence and Trends of Haematological Malignancies in Japan and the United States. Br J Haematol. 2014; 164: 536-545.","DOI":"10.1111\/bjh.12659"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Hiddemann W, Kneba M, Dreyling M et al.<\/i> Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005; 106: 3725-3732.","DOI":"10.1182\/blood-2005-01-0016"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Marcus R, Davies A, Ando K et al.<\/i> Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017; 377: 1331-1344.","DOI":"10.1056\/NEJMoa1614598"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Hiddemann W, Barbui AM, Canales MA et al.<\/i> Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. J Clin Oncol. 2018; 36: 2395-2404.","DOI":"10.1200\/JCO.2017.76.8960"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Casulo C, Byrtek M, Dawson KL et al.<\/i> Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. J Clin Oncol. 2015; 33: 2516-2522.","DOI":"10.1200\/JCO.2014.59.7534"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Freeman CL, Kridel R, Moccia AA et al.<\/i> Early progression after bendamustine-rituximab is associated with high risk of transformation in advanced stage follicular lymphoma. Blood. 2019; 134: 761-764.","DOI":"10.1182\/blood.2019000258"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Roex G, Feys T, Beguin Y et al.<\/i> Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data. Pharmaceutics. 2020; 12: 194.","DOI":"10.3390\/pharmaceutics12020194"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019; 18: 585-608.","DOI":"10.1038\/s41573-019-0028-1"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Jacobson CA, Chavez JC, Sehgal AR et al.<\/i> Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. Lancet Oncol. 2022; 23: 91-103.","DOI":"10.1016\/S1470-2045(21)00591-X"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Neelapu SS, Chavez JC, Sehgal AR et al.<\/i> Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024; 143: 496-506.","DOI":"10.1182\/blood.2023021243"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Ghione P, Palomba ML, Patel AR et al.<\/i> Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed\/refractory follicular lymphoma. Blood. 2022; 140: 851-860.","DOI":"10.1182\/blood.2021014375"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Fowler NH, Dickinson M, Dreyling M et al.<\/i> Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial. Nat Med. 2022; 28: 325-332.","DOI":"10.1038\/s41591-021-01622-0"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Thieblemont C, Dreyling M, Dickinson MJ et al.<\/i> Clinical outcomes of patients with high-risk relapsed\/refractory follicular lymphoma treated with tisagenlecleucel: Phase 2 ELARA 4-year update. Blood. 2024; 144: 3034-3037.","DOI":"10.1182\/blood-2024-201730"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Dreyling M, Fowler NH, Dickinson M et al.<\/i> Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update. Blood. 2024; 143: 1713-1725.","DOI":"10.1182\/blood.2023021567"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Fukuhara N, Kato K, Goto H et al.<\/i> Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial. Int J Hematol. 2023; 117: 251-259.","DOI":"10.1007\/s12185-022-03481-y"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Morschhauser F, Dahiya S, Palomba ML et al.<\/i> Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study. Nat Med. 2024; 30: 2199-2207.","DOI":"10.1038\/s41591-024-02986-9"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Sun LL, Ellerman D, Mathieu M et al.<\/i> Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies. Sci Transl Med. 2015; 7: 287ra70.","DOI":"10.1126\/scitranslmed.aaa4802"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Budde LE, Sehn LH, Matasar M et al.<\/i> Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study. Lancet Oncol. 2022; 23: 1055-1065.","DOI":"10.1016\/S1470-2045(22)00335-7"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Sehn LH, Bartlett NL, Matasar MJ et al.<\/i> Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies. Blood. 2025; 145: 708-719.","DOI":"10.1182\/blood.2024025454"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Shadman M, Bartlett NL, Matasar M et al.<\/i> Mosunetuzumab Continues to Demonstrate Clinically Meaningful Outcomes in Patients with Relapsed and\/or Refractory Follicular Lymphoma after \u22652 Prior Therapies Including Those with a History of POD24: 4-Year Follow-up of a Pivotal Phase II Study. Blood. 2024; 144: 4407.","DOI":"10.1182\/blood-2024-197897"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Linton KM, Vitolo U, Jurczak W et al.<\/i> Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study. Lancet Haematol. 2024; 11: e593-e605.","DOI":"10.1016\/S2352-3026(24)00166-2"},{"key":"22","unstructured":"22 Vitolo U, Jurczak W, Lugtenburg PJ, et al.<\/i> Epcoritamab monotherapy demonstrates deep and durable response at 3-year follow-up in patients with relapsed\/refractory follicular lymphoma. EHA. 2025; Abstract PF881."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Kim TM, Taszner M, Novelli S et al.<\/i> Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma. Ann Oncol. 2024; 35: 1039-1047.","DOI":"10.1016\/j.annonc.2024.08.2239"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Tessoulin B, Harnett J, Cho SG, et al.<\/i> Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed\/Refractory Follicular Lymphoma in the ELM-2 Study. Clin Lymphoma Myeloma Leuk. 2025; 25: e766-e777.e6.","DOI":"10.1016\/j.clml.2025.05.017"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25 Novelli S, Risal A, Namuduri M et al.<\/i> PB2275: Trial in progress: Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2). HemaSphere. 2023; 7: e384923b.","DOI":"10.1097\/01.HS9.0000975832.38492.3b"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Hutchings M, Morschhauser F, Iacoboni G et al.<\/i> Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J Clin Oncol. 2021; 39: 1959-1970.","DOI":"10.1200\/JCO.20.03175"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Morabito F, Martino EA, Nizzoli ME et al.<\/i> Comparative Analysis of Bispecific Antibodies and CAR T-Cell Therapy in Follicular Lymphoma. Eur J Haematol. 2025; 114: 4-16.","DOI":"10.1111\/ejh.14335"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Tix T, Alhomoud M, Shouval R et al.<\/i> Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients. Clin Cancer Res. 2024; 30: 4690-4700.","DOI":"10.1158\/1078-0432.CCR-24-1798"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Rejeski K, Wang Y, Hansen DK et al.<\/i> Applying the EHA\/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 2024; 8: 1857-1868.","DOI":"10.1182\/bloodadvances.2023011767"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Iqbal M, Kumar A, Dreger P et al.<\/i> Clinical Practice Recommendations for Hematopoietic Cell Transplantation and Cellular Therapies in Follicular Lymphoma: A Collaborative Effort on Behalf of the American Society for Transplantation and Cellular Therapy and the European Society for Blood and Marrow Transplantation. Transplant Cell Ther. 2024; 30: 832-843.","DOI":"10.1016\/j.jtct.2024.06.025"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Smirnov S, Mateikovich P, Samochernykh K, Shlyakhto E. Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic. Front Immunol. 2024; 15: 1335424.","DOI":"10.3389\/fimmu.2024.1335424"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Lonez C, Breman E. Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met? Cells. 2024; 13: 146.","DOI":"10.3390\/cells13020146"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33 Hambleton H, Cheah CY. The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma. Expert Opin Investig Drugs. 2025; 34: 245-252.","DOI":"10.1080\/13543784.2025.2500290"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34 Morschhauser F, Bishton M, Eyre TA et al.<\/i> Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed\/refractory follicular Lymphoma: initial results from a phase Ib study. Blood. 2021; 138: 129.","DOI":"10.1182\/blood-2021-145694"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35 Falchi L, Morschhauser F, Linton K et al.<\/i> EPCORE FL-1: phase 3 trial of subcutaneous epcoritamab with rituximab and lenalidomide (R2) vs R2 alone in patients with relapsed or refractory follicular lymphoma. Blood. 2023; 142: 3053.","DOI":"10.1182\/blood-2023-180092"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36 Linton KM, Thompson P, Luminari S, et al. EPCORE FL-2: phase 3 trial of epcoritamab with rituximab and lenalidomide (R2) vs chemoimmunotherapy or R2 in previously untreated follicular lymphoma. 2024 ASCO Annual Meeting. J Clin Oncol. 2024; 42: TPS7084.","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7084"},{"key":"37","unstructured":"37 ClinicalTrials.gov. NCT06549595, A study of AZD0486 plus rituximab in previously untreated follicular lymphoma patients. 2024 Aug."},{"key":"38","unstructured":"38 ClinicalTrials.gov. NCT06284122, Study of mosunetuzumab plus lenalidomide compared to anti-CD20 antibody + chemotherapy in follicular lymphoma FLIPI2-5 (MorningLyte). 2024 May."}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/4\/65_25050\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T04:41:50Z","timestamp":1766810510000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/65\/4\/65_25050\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.25050","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"25050"}}